D.A. Wallach Joins BioSig Technologies Advisory Board
Successful business leader to support Company’s business development
Santa Monica, CA, March 26, 2019 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM), a medical device company developing a proprietary biomedical signal processing platform designed to address an unmet technology need for the $4.6 billion electrophysiology (EP) marketplace, today announced that David-Andrew (D.A.) Wallach, a Los Angeles-based investor, recording artist and songwriter, joined the Advisory Board of the Company.
Mr. Wallach brings to BioSig extensive experience in advising and investing in early stage technology companies, including SpaceX, Doctor on Demand, Ripple, Glympse, Beam and Spotify, where he was the official Artist in Residence.
Forbes selected D.A. as one of its 30 Under 30, and Fast Company named him one of the 100 Most Creative People in Business. In 2015, he launched Inevitable Ventures, an investment partnership with multibillionaire Ron Burkle that supports radical entrepreneurs in areas including healthcare, the life sciences, and financial technologies.
“D.A. has impressed us with his outstanding knowledge of bioelectronic medicine and his successful track record of investing in early stage high-potential technology companies. We are convinced that D.A. will become an invaluable addition to our existing Advisory Board due to his innovative thinking and unique business skills,” commented Kenneth L. Londoner, Chairman and CEO of BioSig Technologies, Inc.
The goal of the Advisory Board is to advise the leadership of BioSig on a range of subjects, including financing, strategy, marketing, government affairs, partnerships and M&A. Current Members of the Board include Los Angeles-based political advisor and business leader Mr. Sim Farar, San Francisco Bay area based Mr. Kent Bennett Williams, CEO and Principal at Vista Asset Management, LLC, and Texas-based Dr. Ramachandra Malya, Medical Director and consulting nephrologist.
“Having spent some time with the Company’s management team, I have been impressed by their dedication to address unmet clinical needs in some of the most challenging areas of medicine. I’m pleased to lend my support to help BioSig grow into a successful commercial company,” commented Mr. Wallach.
About BioSig Technologies
BioSig Technologies is a medical technology company developing a proprietary biomedical signal processing platform designed to improve the electrophysiology (EP) marketplace (www.biosig.com). Led by a proven management team and a veteran, independent Board of Directors, Los Angeles-based BioSig Technologies is preparing to commercialize its PURE EP™ System. The technology has been developed to address an unmet need in a large and growing market.
The Company’s first product, PURE EP™ System is a computerized system intended for acquiring, digitizing, amplifying, filtering, measuring and calculating, displaying, recording and storing of electrocardiographic and intracardiac signals for patients undergoing electrophysiology (EP) procedures in an EP laboratory. The system is indicated for use under the supervision of licensed healthcare practitioners who are responsible for interpreting the data. This novel cardiac signal acquisition and display system is engineered to assist electrophysiologists in clinical decision-making during electrophysiology procedures in patients with abnormal heart rates and rhythms. BioSig’s ultimate goal is to deliver technology to improve upon catheter ablation treatments for the prevalent and potentially deadly arrhythmias, Atrial Fibrillation and Ventricular Tachycardia. BioSig has partnered with Minnetronix on technology development and has received FDA 510(k) clearance for the PURE EP™ System in August 2018.
Forward-looking Statements
This press release contains “forward-looking statements.” Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) our inability to manufacture our products and product candidates on a commercial scale on our own, or in collaboration with third parties; (ii) difficulties in obtaining financing on commercially reasonable terms; (iii) changes in the size and nature of our competition; (iv) loss of one or more key executives or scientists; and (v) difficulties in securing regulatory approval to market our products and product candidates. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (SEC), including the Company’s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC’s website at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.
Natasha Drapeau BioSig Technologies, Inc. Executive Vice President 12424 Wilshire Blvd, Ste 745 Los Angeles, CA 90025 ndrapeau@biosigtech.com 310-620-9320
Released March 26, 2019
